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Abstract
Background: The Xpert MTB/RIF (Cepheid) non-laboratory-based molecular assay has potential to improve the diagnosis of
tuberculosis (TB), especially in HIV-infected populations, through increased sensitivity, reduced turnaround time (2 h), and
immediate identification of rifampicin (RIF) resistance. In a prospective clinical validation study we compared the
performance of Xpert MTB/RIF, MTBDRplus (Hain Lifescience), LightCycler Mycobacterium Detection (LCTB) (Roche), with
acid fast bacilli (AFB) smear microscopy and liquid culture on a single sputum specimen.
Methods and Findings: Consecutive adults with suspected TB attending a primary health care clinic in Johannesburg,
South Africa, were prospectively enrolled and evaluated for TB according to the guidelines of the National TB Control
Programme, including assessment for smear-negative TB by chest X-ray, clinical evaluation, and HIV testing. A single sputum
sample underwent routine decontamination, AFB smear microscopy, liquid culture, and phenotypic drug susceptibility
testing. Residual sample was batched for molecular testing. For the 311 participants, the HIV prevalence was 70% (n=215),
with 120 (38.5%) culture-positive TB cases. Compared to liquid culture, the sensitivities of all the test methodologies,
determined with a limited and potentially underpowered sample size (n=177), were 59% (47%–71%) for smear microscopy,
76% (64%–85%) for MTBDRplus, 76% (64%–85%) for LCTB, and 86% (76%–93%) for Xpert MTB/RIF, with specificities all
.97%. Among HIV+ individuals, the sensitivity of the Xpert MTB/RIF test was 84% (69%–93%), while the other molecular
tests had sensitivities reduced by 6%. TB detection among smear-negative, culture-positive samples was 28% (5/18) for
MTBDRplus, 22% (4/18) for LCTB, and 61% (11/18) for Xpert MTB/RIF. A few (n=5) RIF-resistant cases were detected using
the phenotypic drug susceptibility testing methodology. Xpert MTB/RIF detected four of these five cases (fifth case not
tested) and two additional phenotypically sensitive cases.
Conclusions: The Xpert MTB/RIF test has superior performance for rapid diagnosis of Mycobacterium tuberculosis over
existing AFB smear microscopy and other molecular methodologies in an HIV- and TB-endemic region. Its place in the
clinical diagnostic algorithm in national health programs needs exploration.
Please see later in the article for the Editors’ Summary.
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The tuberculosis (TB) and HIV epidemic in sub-Saharan Africa
continues to pose enormous challenges to public health. South
Africa alone has 1 million people currently receiving HIV
antiretroviral treatment [1,2], the TB incidence is 941 per
100,000 individuals [3], and 9,070 cases of multidrug-resistant
(MDR) TB were reported in 2009 [4]. A recent post-mortem study
from KwaZulu-Natal observed that TB is still the leading cause of
death in HIV+ individuals [5], suggesting that the diagnosis of TB
is made too late to avert mortality. Early diagnosis and
management of TB is also critical to reduce TB transmission in
communities and health care facilities. In 2009, 3 million smears
and 740,000 cultures were performed in South Africa public sector
health care facilities (excluding the KwaZulu Natal province) [6,7].
In recent years, the South African National Health Laboratory
Service scaled up its infrastructure to 249 sites for smear
microscopy and 16 laboratories for Mycobacteria Growth
Indicator Tube (MGIT) culture. While culture remains the most
sensitive method for confirmation of TB, the prolonged turn-
around time, biosafety requirements, and laboratory operational
requirements [8] limit its contribution to clinical decision making
[9]. In 2009, the World Health Organization (WHO) approved
the MTBDRplus assay (Hain Lifescience) for use in smear-positive
specimens and Mycobacterium tuberculosis (M.tb) isolates [10]. To
hasten diagnosis of drug-resistant TB, 20 National Health
Laboratory Service laboratories were earmarked for implementa-
tion of the MTBDRplus assay in South Africa in 2010. The assay
is limited in its application because laboratory infrastructure must
accommodate PCR technology, the assay is not approved for use
in smear-negative cases, and in high-throughput laboratories, it
can take up to 7 d from sample receipt to result reporting [6]. All
these factors limit its potential to contribute to the control of drug-
resistant TB.
The diagnostic development pipeline for both high-throughput
and point-of-care laboratories has seen rapid innovations in the
last decade [11,12] through WHO, Stop TB Partnership, and
Foundation for Innovative New Diagnostics partnerships [13,14].
The most recently WHO-endorsed [15] diagnostic tool, the Xpert
MTB/RIF (Cepheid) assay, has been reported in a multi-country
study to have sensitivities of 98.2% among smear-positive, culture-
positive patients and 72.5% among smear-negative, culture-
positive patients on a single direct Xpert MTB/RIF test compared
to three smears and four culture results [16]. Two sites from South
Africa (Durban and Cape Town) with average HIV infection rates
of 73% were included in this multi-center study. The sensitivity of
the Xpert MTB/RIF assay (three tests performed per participant)
among smear-negative, culture-positive individuals compared to
standard testing (three smears and four culture results per
participant) was 87% (95% CI 62%–96%) for samples from
Durban and 90% (95% CI 79%–96%) for samples from Cape
Town. Other studies have also recently reported the performance
and clinical role of the Xpert MTB/RIF test for detecting TB in
extrapulmonary specimens, with sensitivities of 69% to 85.7% for
tissue specimens and up to 100% in urine and stool specimens
[17,18].
Our study aims to (1) further assess the performance of a single-
sputum Xpert MTB/RIF test against culture-confirmed and
clinically defined cases of TB in a cohort of adults being
investigated for TB with high prevalence of HIV infection from
South Africa (Johannesburg region) and (2) to compare this nucleic
acid amplification technology (NAAT) to two existing molecular
TB assays, the LightCycler Mycobacterium Detection (LCTB)
assay (Roche) and the MTBDRplus assay (Hain Lifescience), for
use directly on sputum.
Methods
Ethics Approval
The study was approved by the University of the Witwatersrand
Human Ethics Review Committee (M070826).
Study Design for Investigation of Potential TB Patients
and Data Management
This prospective study investigated consecutive adults present-
ing with suspected pulmonary TB to a primary health care clinic
in Johannesburg, South Africa, over a 9-mo period between 3
August 2009 and 28 May 2010. Individuals were eligible if they
were $18 y of age and presented with a cough of $2 wk duration,
with or without fever, night sweats, loss of weight, chest pain, and
signs of extrapulmonary involvement (such as lymph nodes,
pleural effusions, or abdominal TB), independent of a history of
TB treatment and acceptance of HIV testing. Persons were
excluded if they were not able to produce sputum, had symptoms
only of extrapulmonary TB, were already on TB treatment, or
required hospital admission.
TB and HIV diagnosis and management were performed
according to South African guidelines [1,19]. As part of routine
care, participants on first presentation were asked to provide two
sputum specimens for smear microscopy. On return (within 1 wk)
for results, participants were invited to participate, and written
informed consent was obtained by the study nurse. At this visit, all
participants were asked to provide a third sputum specimen for
routine smear and culture, and investigational tests. Smear-
positive patients were started on TB treatment. AFB-smear-
negative patients underwent chest radiography and were pre-
scribed amoxicillin. One week later, response to antibiotic therapy
was evaluated, the chest X-ray was read, and the case was assessed
by the study physician. Smear-negative participants with no
response to antibiotics and chest X-ray findings compatible with
TB were initiated on TB treatment. Participants without these
criteria were deemed not to have TB. When in doubt, participants
were referred to a tertiary center for further investigation. For all
participants, data were collected on history of TB, HIV status,
most recent CD4 count, antiretroviral therapy, weight, and oral
temperature at baseline, and a follow-up visit was conducted
approximately 60 d after enrolment. The third sputum sample
underwent routine and immediate N-acetyl-L-cysteine-sodium
hydroxide (NALC)–NaOH decontamination for AFB smear and
MGIT culturing. Residual processed specimen was stored at
270uC, batched, and later used for the three NAAT tests. The
NAAT tests were performed by a scientist, blinded to smear,
culture, and clinical evaluations in an off-site laboratory. All
culture-positive specimens underwent routine MTBDRplus testing
for rifampicin (RIF) and isoniazid (INH) resistance, and where one
or other of these was found present, phenotypic drug sensitivity
testing (DST) was performed. These routine smear and culture
DST results were reported to clinicians and used for patient
management and clinical decision making. The sensitivity,
specificity, and positive and negative predictive values for the
NAAT tests compared to MGIT culture and clinical case
definition were calculated from the results generated from this
single processed sputum sample.
Patient data were recorded using a standardized case report
form, entered periodically into MS Access and exported into
STATA 10 (StataCorp) for analysis. Characteristics between
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Sensitivity, specificity, and positive and negative predictive values
were calculated using either MGIT culture (excluding contami-
nated cultures and non-tuberculous mycobacteria [NTM]) or any
TB (definite, probable, and possible TB) as a gold standard.
NAAT test performance was established for those specimens
where sufficient sample allowed all tests to be done on each
specimen. Analysis was stratified by HIV status and smear
microscopy.
Definitions for TB Case Classification
Participating individuals were classified as ‘‘definite TB’’ if
sputum culture yielded M.tb (with or without positive smears);
‘‘probable TB’’ if M.tb culture was negative/contaminated and at
least one smear was positive for AFB; ‘‘possible TB’’ if smear was
negative for AFB, M.tb culture was negative or contaminated, but
the patient had TB-compatible chest X-ray and any documented
weight gain in response to TB treatment; and ‘‘no TB’’ if smear
was negative for AFB, M.tb culture was negative or contaminated,
symptoms resolved without TB treatment, or if the culture grew
NTM. Individuals who were smear-negative, had a culture that
was negative or contaminated, had a chest X-ray suggestive of TB,
and were initiated on TB treatment, but in whom weight gain was
not documented, were classified as ‘‘indeterminate TB.’’ Partic-
ipants who were not started on TB treatment and were lost to
follow-up or died were also classified as indeterminate TB. The
clinical classification of TB status was performed blinded to the
NAAT results.
Laboratory Methods
The single sputum sample was processed and analyzed using
standard operating procedures in an accredited biosafety level 3
laboratory. Following decontamination using NaOH (1%)–NALC
[20], the specimen was centrifuged and resuspended in approx-
imately 2 ml of phosphate buffer (pH 6.8) to ensure maximum
recovery of bacteria and easy homogenization before aliquots were
removed for testing methodologies. The reconstituted pellet was
used fresh for smear microscopy (,50 ml) and culture (0.5 ml), and
the residual sample was stored at 270uC for NAAT processing.
The MTBDRplus and the LCTB assays were the first NAATs to
be performed in batches of 12 per day (extraction protocols
performed on day 1 followed by amplification the following day).
Once the Xpert MTB/RIF became available (June 2009), 4–5
residual frozen (270uC) specimens stored after completion of the
MTBDRplus and LCTB assays were tested daily. Use of residual
pellet for Xpert MTB/RIF (0.5 ml), MTBDRplus (0.5 ml), and
LCTB (0.1 ml) depended on availability of residual sample after
smear and culture. Any specimen yielding an invalid NAAT result
was re-tested if there was sufficient residual material. This latter
result was used in the sensitivity and specificity calculations.
The sputum smear was stained using standard auramine
reagent and 100 high-power fields examined using a fluorescent
microscope (Olympus CX31 with LED attachment, Wirsam).
Culture was performed using MGIT containing modified Mid-
dlebrook 7H9 broth base, supplemented with MGIT Growth
Supplement and PANTA (BD) and incubated at 37uCu pt o4 2d
in a BACTEC cabinet (Becton Dickinson). Positive cultures were
subjected to Ziehl-Neelsen staining to confirm the presence of
AFB, and to routine MTBDRplus assay to confirm identity as M.tb
and establish INH and RIF susceptibility profiles. Routine
phenotypic MGIT DST was performed when MTBDRplus assay
detected genotypic resistance. All cultures were preserved and
stored. At completion of the study MGIT DST was performed as
per manufacturer’s instructions on additional isolates when this
had not been done before.
All NAAT methods were performed according to the
manufacturer’s instructions and are detailed below. The LCTB
assay is a real-time PCR assay, with bacterial nucleic acid
extracted using the COBAS Amplicor Respiratory Specimen
Preparation kit (Roche Diagnostics) by adding a wash and lysis
solution to the pellet followed by 45 min incubation at 60uC and
addition of a neutralization buffer before the PCR step. PCR is
performed using the LCTB amplification kit (Roche Diagnostics)
designed to amplify a 200-bp fragment of the 16s rRNA gene
containing the hypervariable region A using fluorescent resonance
energy transfer hybridization probes designed for the LightCycler
instrument (Roche Diagnostics). Melting curve analysis is
performed for species differentiation (positive control, 5961.5uC;
negative control not defined; M.tb, 55.961.5uC; M. kansasii,
5961.5uC; M. avium, 47.561.5uC).
The MTBDRplus assay in this study was performed directly on
sputum (irrespective of smear result) and routinely on positive
cultures. In this assay, bacterial nucleic acid extraction is performed
by heat followed by sonication. The PCR is a multiplex
amplification using biotinylated primers, followed by reverse
hybridization onto nitrocellulose strips. A strip contains 17 probes,
including five sample and hybridization controls [21]. The targets
amplifiedare(1)thecore region of therpoBgene, positions505–533,
analyzed for RIF resistance based on eight wild-type probes and
four mutant probes (D516V, H526Y, H526D, and S531L), (2) the
katG gene, analyzed for high-level INH resistance based on the wild-
type S315 and two mutants (AGC to ACC and AGC to ACA, both
producing S315T mutations), and (3) the inhA gene, analyzed for
low-level INH resistance based on the wild-type 1 probe spanning
positions 9–22 and wild-type 2 probe spanning positions 1–12, as
well as four mutation probes (C15T,1A6G, T8C, and T8A) [21].
After several washesand chromogenic substrate reaction, the bound
probes are visually inspected for the presence or absence of control,
wild-type, and mutant bands. Omission of a wild-type band or the
appearance of a mutant band in the resistance-determining region
of a gene indicates the existence of a resistant strain.
The Xpert MTB/RIF assay is a hemi-nested real-time PCR
method that amplifies the 81-bp region of the RIF-resistance-
determining region of the rpoB gene, positions 507–533. A sample
reagent buffer containing NaOH and isopropanol is added in a 2:1
ratio to the processed sputum ensuring a final volume of at least
2 ml. After 15 min of incubation with intermittent hand mixing,
2 ml of the liquefied inactivated sample is added to the cartridge
that contains the wash buffer, reagents for lyophilized DNA
extraction and PCR amplification, and fluorescent detection
probes (five for the rpoB gene and one for an internal control,
Bacillus globigii spores). After the cartridge is placed in the
instrument module, the automated processes include the following:
specimen filtering, sonication to lyse the bacilli and internal
control spores, released DNA collection and combination with the
PCR reagents, amplification, target detection by five-color
fluorescence of overlapping molecular beacon probes, and one-
color fluorescence for the internal control. Results are automat-
ically generated within 2 h and reported as M.tb-negative or -
positive (with semi-quantification) and RIF sensitive or resistant.
The former determination is based on the amplification of any two
rpo gene regions, and the latter determination is based on a
difference of .3.5 amplification cycles of any probe. The Xpert
MTB/RIF assay definition files versions 1.0 and 2.0 were used in
this study. Data analysis for RIF resistance detection, however,
reports results with both the 3.5 and 5.0 cycle threshold differences
as per the manufacturer’s suggestion.
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Patient Population and TB Case Classification
During the study period, 402 potential adults with suspected TB
presented to the clinic, and 319 agreed to participate (Figure 1).
Participants’ mean age was 32.4 y (range 19–75 y); 188 (59%)
were male (Table 1). Most participants (274, 86%) accepted HIV
counseling and testing, among whom 220 (70%) were HIV
positive. Eight patients did not provide a sputum sample for study
procedures and were excluded from the analysis. Among the 311
patients included in the analysis (Figure 1), 88 (28.2%) were smear-
and culture-positive TB cases, 32 (10.2%) had smear-negative,
culture-positive TB, and three (0.9%) had smear-positive, culture-
negative TB. Culture was contaminated for 19 (6.1%) participants.
Among the 188 (60.4%) participants without bacterial confirma-
tion, 50 (26.5%) had possible TB, 58 (30.9%) were classified as not
TB (including five patients with NTM), 31 (16.4%) who started TB
treatment were classified as indeterminate TB because of failure to
gain weight on treatment or because weight at follow-up was not
documented, and 50 (26.6%) were classified as indeterminate TB
because they were not started on treatment and were lost to follow-
up or died.
Case Detection by NAAT Assay
Sufficient sputum sample was available to perform NAAT
analysis using Xpert MTB/RIF in 205 (64%) participants,
MTBDRplus in 283 (89%) participants, and LCTB assay in 280
(88%) participants. There was no significant difference in mean
age, gender, smear microscopy, culture, and HIV status between
patients in whom the different NAAT assays were performed (all
comparative p-values.0.05). Overall, NAAT analysis yielded a
positive result for M.tb in 33% (67/205) by Xpert MTB/RIF, 29%
(83/283) by MTBDRplus, and 31% (88/280) by the LCTB assay.
Among smear-negative participants (n=227), the proportion of
NAAT tests yielding a positive result for M.tb was 11.8% (17/143),
6.7% (13/194), and 6.1% (12/199) for Xpert MTB/RIF,
MTBDRplus, and LCTB, respectively.
Amongst the NAAT tests, the highest rate of indeterminate or
invalid test results was observed for Xpert MTB/RIF (12/205,
5.9%) due to power failures during instrument performance before
an uninterrupted power supply was installed (n=2), inability to
determine presence or absence of M.tb due to improper sample
processing (cartridge error) or PCR inhibition (reported as ‘‘invalid
results’’) (n=5), probe check failure (reported as ‘‘error’’) (n=4),
and operator error (n=1). Of these invalid results there was
sufficient residual material to re-analyze seven samples, which
were then included in the sensitivity and specificity calculations.
Only 2.3% of MTBDRplus assays were indeterminate (due to
positive M.tb control [TUB] band detection issues). None of the
LCTB tests results were indeterminate.
NAAT Sensitivity and Specificity
As detailed in Table 2, compared to MGIT culture, the lowest
sensitivity was observed for smear microscopy (59%, 95% CI
47%–71%), followed by MTBDRplus and LCTB with identical
performance (76%, 95% CI 64%–85%), and Xpert MTB/RIF
(86%, 95% CI 76%–93%), with the highest sensitivity. Sensitivity
estimates did not differ for each NAAT when test results were
included for specimens not having been tested on all NAAT
formats. These results were as follows: smear microscopy, n=289,
sensitivity 59% (95% CI 49%–68%); MTBDRplus, n=254,
sensitivity 74% (95% CI 64%–81%); LCTB, n=236, sensitivity
75% (95% CI 67%–84%); Xpert MTB/RIF, n=182, sensitivity
86% (95% CI 76%–93%). Specificity was 100% for smear
microscopy and .96% for all three NAAT assays. Among
culture-negative TB cases, clinical classifications for participants
with positive NAAT results were as follows: Xpert MTB/RIF,
possible TB (n=1), not TB (n=1), and indeterminate TB status
(n=1); MTBDRplus, indeterminate TB status (n=3); and LCTB,
indeterminate TB status (n=2).
NAAT test performance amongst the cohort of HIV-uninfected
participants had similar sensitivities to test performance on the
entire cohort, although the confidence intervals were wide on
account of the small numbers. However, amongst HIV-infected
participants MTBDRplus and LCTB sensitivities dropped, while
that of Xpert MTB/RIF assay remained similar to that of test
performance in the entire cohort. As expected for all three NAAT
assays, sensitivity was higher among smear-positive than among
smear-negative patients (Table 2). Amongst smear-negative,
culture-positive cases, Xpert MTB/RIF had the highest sensitivity,
61%, detecting 11/18 cases.
The sensitivity for diagnosis of any TB (smear- and/or culture-
positive TB plus possible TB), was 40%, 66%, 51%, 51%, and
58% for smear, culture, MTBDRplus, LCTB, and Xpert MTB/
RIF, respectively.
Detection of Drug Resistance by NAAT
Phenotypic DST results were available for 89 participants, and
identified two MDR strains, five INH mono-resistant strains, and
three RIF mono-resistant strains. Resistance was detected by
MTBDRplus (on sputum or culture) and/or Xpert MTB/RIF in
23 patients (Figure 2). Xpert MTB/RIF identified RIF resistance
in nine patients (using the amplification cycle threshold maximum
3.5 of Xpert MTB/RIF software version 1), of which three were
not reported as RIF-resistant by other DST methods. These are
likely false-positive RIF resistance results, as these samples were
reported as RIF-sensitive by Xpert MTB/RIF when using a
maximum 5.0 amplification cycle threshold (as per Xpert MTB/
RIF software versions 2 and 3). The MTBDRplus test directly on
sputum identified eight patients with RIF-resistant TB, seven of
these had AFB-smear-positive TB. Two were confirmed by MGIT
DST, three were sensitive by MGIT DST, one was culture-
negative, one culture was not done, and one culture was
contaminated. MTBDRplus directly on sputum did not identify
three smear-negative isolates with RIF resistance on phenotypic
MGIT DST. MTBDRplus performed on culture isolates identified
six patients with RIF resistance, of which five were confirmed by
MGIT DST.
INH resistance was detected in ten patients using the
MTBDRplus test directly on sputum. Of these, four were also
resistant on MGIT DST and MTBDRplus on cultured isolates,
four were INH-sensitive by MGIT DST and MTBDRplus done
on cultured isolates, while one was negative for M.tb on MGIT.
MTBDRplus directly on sputum missed INH resistance identified
by MGIT DST in two cases, one of which was AFB-smear-
negative.
Discussion
This is a real-world comparison of different TB sputum
detection technologies, integrated within a national TB screening
guideline. The sensitivity of a single NAAT test compared to a
single MGIT culture in our cohort of South African outpatients
with suspected pulmonary TB (70% HIV-co-infected) was higher
for Xpert MTB/RIF 86% (76%–93%) than MTBDRplus 76%
(64%–85%) and LCTB 76% (64%–85%). This difference in
sensitivities was especially prominent for the diagnosis of
pulmonary TB in HIV-infected individuals (84% versus 70%
Xpert MTB/RIF TB Diagnosis Evaluation in an HIV Setting
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res, resistant; Rx, drug treatment.
doi:10.1371/journal.pmed.1001061.g001
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positive patients (61% versus 28% and 22%, respectively). The
potential underpowering of this limited sample size should be
noted, and it should be clarified that the confidence intervals for all
three NAATs do overlap (even with the sample size increased to
289 by including samples not tested by all assays); however, there is
Table 1. Demographics, clinical characteristics, and results of TB diagnostics in 311 adults with suspected pulmonary TB.
Characteristic
a
All Participants
(n=319)
Smear Microscopy,
MGIT Culture, and
Susceptibility
(n=311) NAAT Performed Directly on Sputum
MTBDRplus (n=283) LCTB (n=280)
Xpert MTB/RIF
(n=205)
Demographics
Age in years, mean (range) 32 (19–75) 32 (19–75) 32 (19–57) 32 (19–57) 32 (19–56)
Male gender, number (%) 188 (59) 185 (59%) 165 (58) 161 (58) 115 (56)
Clinical signs and symptoms at presentation
Duration of cough in weeks, mean (range) 4.1 (0–12) 4 (0–12) 3.9 (0–12) 4.0 (0–12) 3.9 (0–12)
Night sweats 287 (90) 281 (90) 256 (90) 253 (90) 186 (90)
Loss of weight 314 (98) 307 (98) 278 (98) 275 (98) 202 (99)
Chest pain 314 (98) 307 (98) 278 (98) 275 (98) 201 (98)
Concurrent extrapulmonary TB symptoms 31 (10) 30 (10) 26 (9) 26 (9) 25 (12)
Pyrexial at presentation 53 (17) 52 (17) 45 (16) 47 (17) 37 (18)
HIV-related information
Agreed to HIV testing 274 (86) 269 (86) 244 (86) 243 (86) 175 (85)
Tested positive 220 (70) 215 (69) 197 (70) 195 (70) 143 (70)
Tested positive: on ART at presentation 17 (5) 17 (5) 12 (4) 11 (4) 8 (4)
Tested positive: mean CD4 count, cells/ml( n, range) 214 (166, 0–818) 217 (162, 0–818) 215 (151, 0–818) 214 (149, 0–818) 221 (109, 0–818)
Refused testing 43 (14) 42 (13) 38 (14) 36 (13) 30 (15)
Tested negative 54 (17) 54 (17) 47 (17) 48 (17) 32 (16)
Bacteriological classification
b
Smear- and culture-positive 88 (28) 88 (28) 82 (29) 81 (29) 54 (26)
Smear-negative, culture-positive 32 (10) 32 (10) 28 (10) 28 (10) 19 (9)
Smear-negative, culture-negative 166 (52) 166 (53) 150 (53) 148 (53) 115 (56)
Smear-negative, culture contaminated 17 (5) 17 (5) 16 (6) 16 (6) 11 (5)
Clinical classification
Definite TB 120 (38) 120 (39) 110 (39) 109 (39) 73 (36)
Probable TB 4 (1) 3 (1) 2 (1) 2 (1) 1 (1)
Possible TB 51 (16) 50 (16) 45 (16) 44 (16) 40 (20)
No TB 57 (17) 58 (19) 50 (18) 48 (17) 37 (18)
Indeterminate TB status (on TB drugs) 31 (10) 30 (10) 29 (10) 29 (10) 22 (11)
Lost to follow-up, not on TB drugs 56 (18) 50 (16) 47 (17) 48 (17) 32 (15)
M.tb case detection
Percent with indeterminate results
c, number/total
(percent)
NA 19/311 (6.1) 10/283 (3.5) 0/280 (0) 12/205 (5.9)
Percent positive among those with valid results,
number/total (percent)
NA 120/292 (41) 83/273 (30) 88/280 (31) 67/195 (34)
Detection of RIF and/or INH resistance
d
RIF resistance, number/total done (percent) NA 5/89 (6) 8/273 (3) NA 7/195 (4)
INH resistance, number/total done (percent) NA 7/89 (8) 10/273 (4) NA NA
MDR (INH+RIF resistance), number/total done (percent) NA 2/89 (1.0) 3/273 (1)
e NA NA
aValues are number (percent) unless otherwise indicated.
bOne case was smear-positive, culture-negative, and two cases were smear-positive, culture contaminated.
cNo indeterminate smear results; for MGIT culture, indeterminate=contaminated; for Xpert MTB/RIF, indeterminate=error or other result.
dMGIT susceptibility testing done on selected isolates including all cultures where NAAT tests detected resistance.
eTwo cases were culture-positive with phenotypic-confirmed MDR; a third case was culture-negative.
NA, not applicable.
doi:10.1371/journal.pmed.1001061.t001
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assay (76%–93%) and smear microscopy (47%–71%). This
therefore supports the WHO policy that the Xpert MTB/RIF
should be the initial test in adults with HIV infection suspected of
having TB and can replace smear microscopy. The sensitivity of a
single Xpert MTB/RIF assay in our Johannesburg cohort was
slightly lower than in the landmark multi-country study (86%
versus 92.2% overall and 61% versus 72% for smear-negative,
culture-positive specimens) by Boehme et al. [16]. This may be
due to differences in study population, as HIV infection rates
reported in the multi-country study ranged from 1.7% to 76%
across sites [16]. Although the two South African sites (Durban
and Cape Town) involved in the multi-center Xpert MTB/RIF
study [16] reported HIV infection rates (71.4% and 76.1%,
respectively) similar to that found in our Johannesburg population
(70% HIV-infected), breakdown of a single Xpert MTB/RIF test
compared to a single culture result from these sites was not
provided. A recent study [22] performed in a West African
(Tanzania) population using a single Xpert MTB/RIF test
reported sensitivities of 84.1% overall and 61% for smear-
negative, culture-positive isolates, similar to the results in our
study. A more recent study also from South Africa in the Cape
Town population reports even lower sensitivities of 78.1% overall
(performed on raw or processed sputum stored at 220uC) and
55% for smear-negative, culture-positive samples (1 ml unpro-
cessed archived sputum) [23]. This latter study further reported a
sensitivity of the Xpert MTB/RIF assay among HIV-infected
individuals of 69.6% (n=46), which, although lower than our
study findings (84%, n=124), was not significantly different
(p=0.09) from the sensitivity reported for the HIV-uninfected
group in their study (82.9%, n=82) [23]. All together, these studies
and our findings provide evidence of the much improved
Table 2. Test performance (including comparison to clinical case definitions) for smear microscopy, MGIT culture, MTBDRplus
directly on sputum, LCTB, and Xpert MTB/RIF assays stratified by smear microscopy and HIV status.
Test Performance Measure
a Smear Microscopy MGIT Culture NAAT Performed Directly on Sputum
MDRTBplus LCTB
Xpert MTB/
RIF
Comparison to MGIT culture (n=177)
Sensitivity 59 (47–71) NA 76 (64–85) 76 (64–85) 86 (76–93)
Specificity 100 (96–100) 97 (92–99) 98 (93–99) 97 (92–99)
PPV 100 (91–100) 94 (84–98) 92 (87–99) 95 (86–99)
NPV 80 (72–86) 87 (79–92) 87 (79–92) 92 (85–96)
Comparison to MGIT culture (HIV-positive
cohort only, n=124)
Sensitivity 54 (38–69) NA 70 (54–83) 70 (54–83) 84 (69–93)
Specificity 100 (95–100) 96 (89–99) 98 (93–100) 96 (89–99)
PPV 100 (85–100) 91 (76–98) 97 (83–100) 92 (79–98)
NPV 80 (70–87) 85 (76–92) 86 (77–92) 92 (84–97)
Comparison to MGIT culture (HIV-negative
cohort only, n=26)
Sensitivity 66 (35–90) 75 (43–95) 75 (42–94) 83 (52–98)
Specificity 100 (70–100) 100 (76–100) 100 (76–100) 100 (76–100)
PPV 100 (63–100) 100 (66–100) 100 (66–100) 100 (69–100)
NPV 79 (52–93) 82 (56–96) 82 (56–96) 88 (62–98)
Comparison to clinical case definition ‘‘Any
TB including definite, probable, and possible
TB’’ (n=177)
Sensitivity 40 (30–50) 66 (56–75) 51 (40–60) 51 (40–60) 58 (48–68)
Specificity 100 (95–100) 100 (95–100) 96 (88–99) 97 (91–99) 97 (91–99)
PPV 100 (91–100) 100 (94–100) 94 (84–98) 96 (87–99) 97 (88–99)
NPV 56 (47–64) 69 (59–77) 59 (50–68) 60 (51–68) 63 (54–72)
Percent detection
b
Smear-positive, culture-positive
c, number/total (percent) 40/49 (81) 49/49 (100) 46/49 (94) 47/49 (96) 47/49 (96)
Smear-negative, culture-positive
d, number/total (percent) 0/18 (0) 18/18 (100) 5/18 (28) 4/18 (22) 11/18 (61)
Smear-negative, culture-negative, number/total (percent) 0/107 (0) 0/107 (0) 3/107 (3) 1/107 (1) 3/107 (3)
All tests performed on the same 177 sputum specimens. Confidence intervals 95%.
aAll values are percent (95% CI) unless otherwise indicated.
HIV status distribution was as follows: HIV-positive, 124; HIV-negative 26; HIV status unknown, 27.
bAmongst 177 cases where all tests were done, 49 were smear-positive, culture-positive; 18 were smear-negative, culture-positive; 107 were smear-negative, culture-
negative; in three cases NTM was isolated.
cWhere any of the three smears taken during the study period were positive.
dWhere all of the three smears taken during the study period were negative.
doi:10.1371/journal.pmed.1001061.t002
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microscopy. Our findings further show the superior sensitivity of
the Xpert MTB/RIF compared to the MTBDRplus and the
LCTB assays, especially in the context of HIV co-infection. Some
studies have reported Xpert MTB/RIF performance compared to
other NAATs not evaluated in our study: the sensitivity of the
Xpert MTB/RIF is reported to be higher than that of COBAS
Amplicor MTB (Roche) (94% versus 86.8%) and similar to that of
ProbeTec ET MTB Complex Direct Detection Assay (BD) (83.7%
versus 83.9%) [16]; the sensitivity of the Xpert MTB/RIF assay is
reported to be 79%, compared to an in-house IS6110-TaqMan
real-time PCR assay with 84% sensitivity [24]; the Xpert MTB/
RIF is suggested to be as good as the Gen-Probe MTB (Gen-
Probe), but no data are available [25].
In our study, the decreased sensitivities of all tests (smear,
culture, and NAATs) when using ‘‘clinical TB’’ as a gold standard
instead of MGIT culture reflect the paucibacillary nature of
pulmonary TB in a community of high HIV seroprevalence and
the preference of clinicians to potentially overtreat than undertreat
TB in HIV-infected individuals. Amongst these cases, confirma-
tion of TB could be improved through additional MGIT cultures
or additional Xpert MTB/RIF assays [16]. However, we elected
to remain with this study design (one specimen sample for all
investigational NAATs and MGIT culture) as it more closely
Figure 2. Heat map showing drug susceptibility profiles from 23 samples based on Xpert MTB/RIF, MTBDRplus on sputum,
MTBDRplus on cultured isolates, and phenotypic culture (MGIT DST). The 23 samples were from a cohort of 311 participants. The heat map
shows samples represented in rows and assigned numerical patient identifiers and testing methodologies in columns. Three colors are used to
indicate the results: red, resistant; green, sensitive; yellow, not done, negative for M.tb, contaminated, or inconclusive. The samples are sorted into
AFB-negative or -positive, with RIF and INH profiles in blocks side by side. Two columns are shown for the RIF results generated from the Xpert MTB/
RIF using the amplification cycle threshold maximums 3.5 and 5.0. MDR TB was identified in two patients.
doi:10.1371/journal.pmed.1001061.g002
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guidelines, and may remain practicable should Xpert MTB/RIF
be implemented into routine diagnostic algorithms.
We further compared the assays’ performances for the diagnosis
of drug-resistant TB. Xpert MTB/RIF can detect mutations in the
rpoB gene which occur in 95%–99% of RIF-resistant isolates [26–
29] and are considered a good indicator for MDR TB [30]. The
MTBDRplus assay is able to detect katG and inhA gene mutations
that confer INH resistance in phenotypically resistant INH isolates,
in addition to rpoB gene mutations. The LCTBassay does not detect
mutations in resistance-determining regions of M.tb. Regarding RIF
resistance, over-reporting has previously been described for the
Xpert MTB/RIF assay compared with phenotypic DST [16].
Boehme et al. [16] further investigated isolates reported by Xpert
MTB/RIF as RIF-resistant, and established by gene sequencing the
presence of resistance-associated rpoB mutations or mixed infection
with wild-type and mutant strains in the same culture. We did not
genotype our resistant isolates further but initially observed a higher
yield of the Xpert MTB/RIF assay for diagnosis of RIF resistance
compared to MTBDRplus or MGIT DST. On re-evaluation using
the new recommended software amplification cycle threshold of
maximum 5.0, no discrepancies with MTBDRplus were found. We
also observed a loss of detection of RIF and INH resistance between
MTBDRplus directly on sputum and MTBDRplus on culture
isolate. This difference could be due to the presence of a mixed-
drug-susceptible and drug-resistant population with different
growth potentials [31].
Overall, of 23 resistant samples detected by any methodology
amongst 311 patients, we found nine discrepancies between
phenotypic and genotypic results. In practice, discrepancies may
leadtoinappropriatemanagementofTB,withunnecessaryexposure
to potentially toxic drugs or suboptimal treatment; however, the
small sample size limits the full powering for DST accuracy testing.
In addition to the investigation of the Xpert MTB/RIF and
MTBDRplus NAAT tests, this studyalsoinvestigatesthe new LCTB
NAAT assay, which may find place in laboratory settings for cost-
effective high-throughput rapid screening (76% sensitive) in place of
smear microscopy (59% sensitivity), with similar turnaround times.
A limitation of our study is that NAAT assays were performed
on frozen aliquots, while smear microscopy and MGIT culture
were performed on fresh samples. This may have impaired M.tb
detection, and reduced the sensitivity of the NAATs in comparison
to culture. In addition, the resuspension of the single processed
sputum in ,2 ml of buffer, as opposed to the recommended
1.5 ml, increased the sample volume, resulting in a dilution and
possibly reduced NAAT sensitivities. Freezing of sample aliquots
may have caused bacterial disintegration, and consequent
suboptimal performance of Xpert MTB/RIF, which relies on
capturing whole (intact) bacteria. Several other studies too have
recently reported Xpert MTB/RIF assay performance using
stored samples: 217 samples from three sites within the western
United States processed by NALC-NaOH and then stored at
280uC showed sensitivities of 98% for smear-positive and 72% for
smear-negative samples [25]; 125 smear-negative clinical speci-
mens processed by NALC-NaOH and then stored at 280uC for
up to 10 y had reported sensitivities (on 1 ml) of 75.3% on the
Xpert MTB/RIF assay [32]; 97 clinical specimens processed by
NALC-NaOH and then stored at 280uC before Xpert MTB/RIF
testing had reported sensitivities of 79% [24]; and the Cape Town
study also tested the Xpert MTB/RIF assay using archived
specimens, as mentioned above [23]. Despite these limitations,
Xpert MTB/RIF still showed superior performance among all
NAATs. In favor of the Xpert MTB/RIF assay design is the
sample input volume of processed sputum of 500 ml, compared to
100 ml used for the LCTB assay, and product detection using
automated, more sensitive fluorescence, not visual detection as
with the MTBDRplus assay. Although the Xpert MTB/RIF assay
invalid rate appeared higher than previously documented, the use
of an uninterrupted power supply did improve result reporting,
and should therefore be considered during field implementation.
It has been estimated that the diagnosis of active TB with a
sputum-based assay with a sensitivity of 85% and specificity of 97%
has the potential to save more than 400,000 lives per year [33]. The
only NAAT assay that achieved these targets in our study was Xpert
MTB/RIF. Combined with the fast turnaround time and the
potential for point-of-care implementation (latter not evaluated in
this study), the assay could revolutionize TB diagnosis. Already in a
first implementation study of the Xpert MTB/RIF assay [34] in
sites in South Africa, Peru, and India, and totaling 6,648
participants, use of the Xpert MTB/RIF assay reduced the median
treatmentdurationforsmear-negative TBfrom56 dto5 d.Further
research is needed to determine how best to integrate this assay into
currentTBdiagnosticalgorithmsandtoimproveourunderstanding
of the prevalence and causes of discrepant drug resistance profiles.
The implementation of point-of-care testing including NAATs
such as the Xpert MTB/RIF will need to be assessed for
appropriate management of quality assurance, the adequacy of
clinic resources (infrastructural and human), data collection,
acceptance by patients and health care providers, and affordabil-
ity, especially in resource-constrained settings.
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Background. Tuberculosis (TB)—a contagious bacterial
infection that mainly affects the lungs—is a global public
health problem. In 2009, 9.4 million people developed TB,
and 1.7 million people died from the disease; a quarter of
these deaths were in HIV-positive individuals. People who
are infected with HIV, the virus that causes AIDS, are
particularly susceptible to TB because of their weakened
immune system. Consequently, TB is a leading cause of
illness and death among people living with HIV. TB is caused
by Mycobacterium tuberculosis, which is spread in airborne
droplets when people with the disease cough or sneeze. Its
characteristic symptoms are a persistent cough, night
sweats, and weight loss. Diagnostic tests for TB include
sputum smear analysis (the microscopic examination of
mucus brought up from the lungs by coughing for the
presence of M. tuberculosis) and mycobacterial liquid culture
(in which bacteriologists try to grow M. tuberculosis from
sputum samples and test its drug sensitivity). TB can usually
be cured by taking several powerful drugs daily for at least
six months.
Why Was This Study Done? Mycobacterial culture is a
sensitive but slow way to diagnose TB. To halt the disease’s
spread, it is essential that TB—particularly TB that is resistant
to several treatment drugs (multidrug-resistant, or MDR,
TB)—is diagnosed quickly. Recently, several nucleic acid
amplification technology (NAAT) tests have been developed
that rapidly detect M. tuberculosis DNA in patient samples
and look for DNA changes that make M. tuberculosis drug-
resistant. In December 2010, the World Health Organization
(WHO) endorsed Xpert MTB/RIF—an automated DNA test
that detects M. tuberculosis and rifampicin resistance (an
indicator of MDR TB) within two hours—for the investigation
of patients who might have TB, especially in regions where
MDR TB and HIV infection are common. TB diagnosis in HIV-
positive people can be difficult because they are more likely
to have smear-negative TB than HIV-negative individuals. In
this prospective study, the researchers compare the
performance of Xpert MTB/RIF on a single sputum sample
with that of smear microscopy, liquid culture, and two other
NAAT tests (MTBDRplus and LightCycler Mycobacterium
Detection) in adults who might have TB in Johannesburg
(South Africa), a region where many adults are HIV-positive.
What Did the Researchers Do and Find? The researchers
evaluated adults with potential TB attending a primary
health care clinic for TB according to national guidelines and
determined their HIV status. A sputum sample from 311
participants underwent smear microscopy, liquid culture,
and drug susceptibility testing; 177 samples were also tested
for TB using NAAT tests. They found that 70% of the
participants were HIV-positive and 38.5% had culture-
positive TB. Compared to liquid culture, smear microscopy,
MTBDRplus, LightCycler Mycobacterium Detection, and
Xpert MTB/RIF had sensitivities of 59%, 76%, 76%, and
86%, respectively. That is, assuming that liquid culture
detected everyone with TB, Xpert MTB/RIF detected 86% of
the cases. The specificity of all the tests compared to liquid
culture was greater than 97%. That is, they all had a low
false-positive rate. Among people who were HIV-positive, the
sensitivity of Xpert MTB/RIF was 84%; the sensitivities of the
other NAAT tests were 70%. Moreover, Xpert MTB/RIF
detected TB in 61% of smear-negative, culture-positive
samples, whereas the other NAATs detected TB in only
about a quarter of these samples. Finally, although some TB
cases were identified as drug-resistant by one test but drug-
sensitive by another, the small number of drug-resistant
cases means no firm conclusions can be made about the
accuracy of drug resistance determination by the various
tests.
What Do These Findings Mean? Although these findings
are likely to be affected by the study’s small size, they
suggest that Xpert MTB/RIF may provide a more accurate
rapid diagnosis of TB than smear microscopy and other
currently available NAAT tests in regions where HIV and TB
are endemic (i.e., always present). Indeed, the reported
accuracy of Xpert MTB/RIF for TB diagnosis—85% sensitivity
and 97% specificity—has the potential to save more than
400,000 lives per year. Taken together with the results of
other recent studies (including an accompanying article by
Lawn et al. that investigates the use of Xpert MTB/RIF for
screening for HIV-associated TB and rifampicin resistance),
these findings support the WHO recommendation that Xpert
MTB/RIF, rather than smear microscopy, should be the initial
test in HIV-infected individuals who might have TB.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001061.
N This study is further discussed in a PLoS Medicine
Perspective by Carlton Evans; a related PLoS Medicine
Research Article by Lawn et al. is also available
N WHO provides information (in several languages) on all
aspects of tuberculosis, including general information on
tuberculosis diagnostics and specific information on the
Xpert MTB/RIF test; further information about WHO’s
endorsement of Xpert MTB/RIF is included in a recent
Strategic and Technical Advisory Group for Tuberculosis
report
N WHO also provides information about tuberculosis and HIV
N The US National Institute of Allergy and Infectious Diseases
has detailed information on tuberculosis and HIV/AIDS
N The US Centers for Disease Control and Prevention also has
information about tuberculosis, including information on
the diagnosis of and on tuberculosis and HIV co-infection
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on HIV-related tuberculosis (in English and Spanish)
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